Pharmaceuticals · Switzerland
Track Roche Holding AG
Add to watchlistRoche Holding AG is one of the world’s largest healthcare companies, with operations across pharmaceuticals and diagnostics. Headquartered in Switzerland, the company develops medicines and diagnostic technologies used by patients, doctors, hospitals, laboratories, and healthcare systems across global markets. Its pharmaceutical business focuses on areas such as oncology, immunology, neuroscience, ophthalmology, infectious diseases, and rare conditions, while its diagnostics business provides testing systems and tools that support disease detection, monitoring, and personalised medicine.
Roche’s strength comes from the combination of its drug development capability and its global leadership in diagnostics. This gives the company a distinctive position across both treatment and testing, allowing it to support more targeted healthcare decisions. As demand grows for cancer therapies, advanced diagnostics, genomic testing, chronic disease management, and personalised medicine, Roche remains one of the most important companies in global healthcare.
Need deeper analysis on Roche Holding AG? ET&A Professional includes full company notes, valuations and models — or commission bespoke research.
Mobile money began as a convenient way to send and receive cash. Today, Africa’s largest telecom operators are moving into lending, savings, insurance and investment products. MTN’s interest in acquiring banking licences raises a bigger question: could the mobile network eventually become more important to African consumer finance than the traditional bank branch?
ET&A Research · 27 August 2026
Africa has the labour force, natural resources and increasingly the capital required to build a larger manufacturing economy. But shortages of technicians, engineers, production managers and job-ready industrial workers are becoming a more important constraint on how quickly the continent can industrialise.
ET&A Research · 25 August 2026
A low price-to-earnings ratio does not automatically mean a stock is cheap, just as a high P/E ratio does not automatically mean it is expensive. The ratio only becomes useful when investors understand what the market is pricing into those earnings.
ET&A Research · 24 August 2026
